Current Landscape of Immunotherapy in Genitourinary Malignancies

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Scopus citations

Abstract

The past decade has witnessed a revolution of immune checkpoint inhibitors in the treatment of multiple tumor types, including genitourinary cancers. Immune checkpoint inhibitors improved the treatment outcomes of patients with metastatic renal cell carcinoma and metastatic urothelial carcinoma. In prostate cancer, the role of immunotherapy with checkpoint inhibitors is not yet established, but clinical trials investigating their use are ongoing. Other immunotherapeutic approaches that have been explored in these malignancies include cytokines, vaccines, and cellular therapy. Ongoing studies are exploring the use of immunotherapy combinations as well as combination with chemotherapy and targeted therapy in these types of tumors. The use of immunotherapy beyond the metastatic setting is an active area of research. Moreover, there is a great interest in biomarker development to predict response to immunotherapy and risk of toxicity. This chapter is a comprehensive review of the immunotherapeutic approaches, both approved and investigational, for the treatment of renal cell carcinoma, urothelial carcinoma, and prostate cancer.

Original languageEnglish (US)
Title of host publicationAdvances in Experimental Medicine and Biology
PublisherSpringer
Pages107-147
Number of pages41
DOIs
StatePublished - 2020

Publication series

NameAdvances in Experimental Medicine and Biology
Volume1244
ISSN (Print)0065-2598
ISSN (Electronic)2214-8019

Keywords

  • Cellular therapy
  • Checkpoint inhibitors
  • Cytokines
  • Immunotherapy
  • Prostate cancer
  • Renal cell carcinoma
  • Urothelial carcinoma
  • Vaccines

ASJC Scopus subject areas

  • General Biochemistry, Genetics and Molecular Biology

Fingerprint

Dive into the research topics of 'Current Landscape of Immunotherapy in Genitourinary Malignancies'. Together they form a unique fingerprint.

Cite this